Presentation_PavelPetrycki_v4

C o n t a c t : P a v e l P e t r y c k i

a r t z o n e@symp a t i c o . c a

4 1 6 . 9 4 9 . 4 6 2 6 c e l l

F e b r u a r y 2 , 2 0 1 5

work samplesbeer • cars • drugs and everything in between

Pavel Petrycki

GET† 5 BONUS SONGS,

FROM OVER 3 MILLION.Inside Specially Marked 24-Can Packs.

ETET†† O S SO GOBONUS SONGONUS SONG5 BBO

†Must be legal drinking age. Offer expires on October 31, 2012. Each unique PIN code can be redeemed online for 5 bonus music downloads at kingclub.ca/music. All downloads are for promotional use only, not for resale, no cash value. Valid in Canada only. Subject to provider’s terms & conditions. Full details available at kingclub.ca. ®/MD Anheuser-Busch, Inc.

work samplesPavel Petryckia r t z o n e@symp a t i c o . c a 4 1 6 . 9 4 9 . 4 6 2 6 c e l l







ANEW NIGHTIS HERE.

®/MD Anheuser-Busch, Inc.

AHTGNI

T

HISWNE

ERE HHTGNI

E.T

A

NEWNIGHT IS HERE.



ERE

E H IS

T HGWE

ERE

IG NNE

E H IS

A

WE

A

NE

A


NEW NIGHTIS HERE.

A

A

A

A

N

NE

E

WE

W

W

N

N

NI

GI

G

GH

H

TH

T

N

NE

E

WE

W

W

N

N

NI

GI

G

GH

H

TH

T

N

NE

E

WE

W

W

N

N

NI

GI

G

GH

H

TH

T

I N

S NE

S E

S WE

HW

HW

HN

EN

ENI

EGI

RG

RGH

RH

ETH

ET

I

S

S

S

H

H

H

E

E

E

R

R

R

E

E

I

S

S

S

H

H

H

E

E

E

R

R

R

E

E

I

S

S

S

H

H

H

E

E

E

R

R

R

E

E

I

S

S

S

H

H

H

E

E

E

R

R

R

E

E

.

.

Labatt Brands at Grip Limited

THE BRAND

1

1

1

PROGRAM OVERVIEW

HOW IT WORKS

PATIO DOMINATION

ARE YOU IN?


†Must be legal drinking age. Limited time offer. W

GET† A BUD LIGHT LIME T-SHIRT WITH THE PURCHASE OF A BUD LIGHT & BUD LIGHT LIME 12-CAN MIXER PACK.

*TM/MC Anheuser-Busch, Inc.

A SUBTLE TWIST OF LIME AND MINT.

Labatt Brands at Grip Limited


Acura at Grip Limited


1 1

The all-new 2012 CR-V is almost here.

The 2012 is coming.

75512A028E

Model shown with accessories.

T he a -n all ew 2 2012 2 CR V is - R s alm mos st he e. er028E5512A7

“…unparalleled breadth of talent and goodness.”

For the 26th time in 30 years, the safety, quality and reliability of Honda’s Accord has made it one of Car and Driver’s 10Best.

- Car and Driver, January 2012

honda.ca

2011

2006

2001

1994

1987

20102009

2004

1999

1990

1985

2005

2000

1991

1986

2008

2003

1998

1989

1984

2007

2002

1995

1988

1983

2012

4:45 PM

Honda at Grip Limited


Accessories may not be available on all trim levels.

See honda.ca for a complete list of accessories.© 2012 Honda Canada Inc., 180 Honda Boulevard, Markham, Ontario, Canada L6C 0H9Specifications are based on information available at the time of printing and are subject to change without notice. See a sales associate for details.Printed in Canada. 03/12 75512A025E

CR-Z122-hp, 1.5-litre, 16-valve, SOHC, i-VTEC® 4-cylinder with Integrated Motor Assist IMA® • Close-ratio 6-speed manual transmission (MT) • Available continuously variable transmission (CVT) • 4-wheel Anti-lock Braking System (ABS) with Electronic Brake Distribution (EBD) and Brake Assist • 16" aluminum-alloy wheels • 360-watt AM/FM/CD Premium audio system with MP3/Windows Media® Audio playback capability and7 speakers including subwoofer • Automatic climate control with air-filtration system • Body-coloured door handles • Body-coloured heated folding power side mirrors with integrated turn indicators • Creep-aid system (CVT only) • Drive-by-Wire Throttle System™ • Driver’s and front passenger’s illuminated vanity mirrors • Dual-stage, dual-threshold front airbags (SRS) • Electric power-assisted rack-and-pinion steering (EPS) • Folding cargo tray behind front seats • Front side airbags with passenger-side Occupant Position Detection System (OPDS) • HandsFreeLink™-bilingual Bluetooth® wireless mobile phone interface • High-Intensity Discharge (HID) headlights • Hill Start Assist (MT only) • MacPherson strut front suspension • MP3/auxiliary input jack • Power-assisted, ventilated front disc brakes • Power windows with auto-up/down driver’s window • Programmable automatic power door locks • Steering wheel-mounted audio controls • Steering wheel-mounted cruise control • Three-mode drive system (Sport, Normal, Econ) • Tilt and telescoping steering column • Variable intermittent windshield wipers • Vehicle Stability Assist (VSA®) with Traction Control

PREMIUM PACKAGEAdds to or replaces CR-Z features:Heated front seats • Honda Satellite-Linked Navigation System™ with bilingual Voice Recognition and steering wheel-mounted controls • Leather-trimmed seats

Accessories17" alloy wheels • All-season floor mats • Ashtray – cupholder style • Auto-dimming day/night rearview mirror with compass • Body side mouldings • Car cover • Cargo mat • Cargo tray • Door edge film • Door sill trim • Door sill trim – illuminated • Driver’s armrest with storage compartment • Engine block heater • Front lip spoiler • Full nose mask • Rear bumper appliqué • Rear diffuser • Side accent spoiler • Splash guards • Tailgate spoiler • Wheel locks • Wheel locks – unexposed

CR-Z20

12

1 1 2:33 PM

Crosstour

Yeah, it does that.

2012

02

201

does ah eYYe

.s thath, it

2012

Yeah, it does that.

THE OFFICIAL VEHICLE OF THE TORONTO BLUE JAYS™

1 1

20

210

E J

™SYAAYE J

ah eYYe h it does

ah eYYe s thath, it

. t

Honda at Grip Limited

13 12

2.68

warfarin Pradax 150 mg BID

1.38

Effi cacyDemonstrated signifi cantly superior effi cacy in BOTH ischemic and hemorrhagic stroke vs. warfarin, in the RE-LY trial with >18,000 AF patients1

*A randomized non-inferiority trial of 18,113 AF patients at risk of stroke. Patients received dabigatran 110 mg BID or 150 mg BID (blinded arms) or adjusted doses of warfarin (unblinded arm).

Effi cacy: PrPRADAX®150 mg BID vs. warfarin

Bleeding is the most relevant side effect of PRADAX; bleeding of any type or severity occurred in long-term treatment in 16.5% of patients with atrial fi brillation treated for the prevention of stroke and systemic embolism. As with all anticoagulants, PRADAX should be used with caution in circumstances associated with an increased risk of bleeding. Bleeding can occur at any site during therapy with PRADAX. Patients at high risk of bleeding should not be prescribed PRADAX. Close clinical surveillance (looking for signs of bleeding or anemia) is recommended throughout the treatment period, especially if risk factors are combined. Should severe bleeding occur, treatment with PRADAX must be discontinued and the source of bleeding investigated promptly. Patients who develop acute renal failure must discontinue PRADAX. Renal function test should be performed before initiation of therapy and when suspected that the renal function could decline, to exclude patients with severe renal impairment. The measurement of dabigatran-related anticoagulation may be helpful to avoid excessive high exposure to dabigatran in the presence of additional risk factors.1

Safety profi lePradax demonstrated lower risk of intracranial bleeding† in AF vs warfarin1*§

Annual Rate of Intracranial Bleeding (%)

* Adapted from Pradax Product Monograph. A randomized non-inferiority trial of 18,113 AF patients at risk of stroke. Patients received dabigatran 110 mg BID or 150 mg BID (blinded arm) or adjusted doses of warfarin (unblinded arm).

§Intracranial bleeding: dabigatran 150 mg BID (n=6076, no. of events=38) vs. warfarin (n=6022, no. of events=90).

†Intracranial bleeding includes adjudicated hemorrhagic stroke, subarachnoid, and/or subdural bleeding.

0.8

0.3

p<0.0001

Stroke or Systemic Embolism1*

No. of Events Annual Rate (%)

Warfarinn=6022 202 1.7

Pradaxn=6076 134 1.1

35%p=0.0001

Ischemic Stroke1*



Pradaxn=6076 103 0.9

25%p=0.03

Hemorrhagic Stroke1*



Pradaxn=6076 12 0.1

74%p<0.001

Approximately 80% of all strokes are ischemic5

12-13 0 2:11 PM


PRADAX (dabigatran etexilate) est indiqué pour la prévention de l’AVC et de l’embolie systémique chez les patients atteints de fi brillation auriculaire pouvant recevoir une anticoagulothérapie.

PRADAX est contre-indiqué chez les patients atteints de ce qui suit : insuffi sance rénale grave (ClCr < 30 mL/min); manifestations hémorragiques, diathèse hémorragique ou patients présentant une altération spontanée ou pharmacologique de l’hémostase; lésions associées à un risque de saignement signifi catif sur le plan clinique, telles qu’un infarctus cérébral étendu (hémorragique ou ischémique) au cours des 6 derniers mois, ulcère gastrique en évolution avec saignement récent; traitement concomitant par inhibiteurs puissants de la P-glycoprotéine tels que le kétoconazole administré par voie orale et hypersensibilité connue au dabigatran, au dabigatran etexilate ou à tout autre ingrédient contenu dans la préparation du produit ou composant du contenant.

Le saignement est l’effet secondaire le plus important de PRADAX; un saignement de toute nature ou gravité a été observé chez 16,5 % des patients souffrant de fi brillation auriculaire ayant reçu un traitement de longue durée visant à prévenir l’AVC et l’embolie systémique. Comme c’est le cas avec tous les anticoagulants, PRADAX devrait être utilisé avec précaution lorsqu’il existe un risque plus élevé de saignement. Un saignement peut survenir n’importe où dans l’organisme durant le traitement par PRADAX. PRADAX ne devrait pas être prescrit aux patients à risque élevé de saignement. Une surveillance clinique étroite (visant à détecter tout signe de saignement ou d’anémie) est recommandée durant la période de traitement, surtout en présence de facteurs de risque. En cas de saignement grave, le traitement par PRADAX doit être interrompu et la source du saignement rapidement recherchée. Les patients qui présentent une insuffi sance rénale aiguë pendant le traitement par PRADAX devraient cesser de prendre ce médicament. La fonction rénale devrait être évaluée avant l’instauration du traitement et si l’on soupçonne que la fonction rénale pourrait se détériorer afi n d’exclure les patients atteints d’insuffi sance rénale grave.

L’innocuité et l’effi cacité de PRADAX n’ont pas été évaluées chez des patients présentant des valvules cardiaques mécaniques ou ceux atteints de rhumatisme cardiaque signifi catif sur le plan hémodynamique, dont une sténose mitrale. Par conséquent, l’administration de PRADAX n’est pas recommandée.

Les agents pouvant augmenter le risque d’hémorragie ne devraient pas être administrés en association avec PRADAX ou, si nécessaires, devraient être administrés avec précaution durant le traitement par PRADAX. L’administration concomitante de dronédarone augmente l’exposition à PRADAX et n’est pas recommandée. Le risque de saignement pourrait être plus élevé chez les patients qui reçoivent un traitement concomitant par inhibiteur sélectif du recaptage de la sérotonine (ISRS). Chez les patients souffrant de fi brillation auriculaire et recevant un traitement visant à prévenir l’AVC et l’embolie systémique, l’administration concomitante d’antiplaquettaires par voie orale (comme l’AAS et le clopidogrel) et d’AINS augmente le risque de saignement d’environ deux fois. L’administration concomitante de PRADAX et de l’inducteur puissant de la P-gp rifampicine diminue les concentrations plasmatiques de dabigatran et, par conséquent, devrait être évitée. Veuillez consulter la monographie du produit pour obtenir des renseignements additionnels sur les traitements qui augmentent le risque d’hémorragie.

Prière de consulter la monographie du produit pour l’information sur l’ajustement posologique chez certaines populations particulières.

Les manifestations indésirables les plus courantes observées chez 1 % des patients ayant reçu PRADAX à 150 mg bid et à 110 mg bid comprenaient : anémie (1,6 %, 1,2 %), épistaxis (1,1 %, 1,1 %), hémorragie gastro-intestinale (4,6 %, 3,3 %), hémorragie uro-génitale (1,4 %, 1,1 %), douleur abdominale (2,2 %, 2,3 %), diarrhée (1,2 %, 1,3 %), dyspepsie (3,9 %, 4,2 %) et nausée (1,2 %, 1,0 %), respectivement. Des réactions indésirables gastro-intestinales sont survenues plus fréquemment avec le dabigatran etexilate qu’avec la warfarine, et avaient trait à la dyspepsie (incluant douleur abdominale supérieure, douleur abdominale, malaise abdominal, malaise épigastrique) ou à des symptômes de pseudo-gastrite (incluant refl ux gastro-œsophagien, œsophagite, gastrite érosive, hémorragie gastrique, gastrite hémorragique, gastrite érosive hémorragique et ulcère gastro-intestinal). Une hémorragie gastro-intestinale est survenue plus fréquemment avec le traitement par PRADAX à 150 mg bid et à 110 mg bid (4,6 % et 3,3 %, respectivement) comparativement au traitement par warfarine (2,6 %). Le mécanisme sous-jacent expliquant le taux plus élevé d’hémorragies gastro-intestinales avec PRADAX n’a pas été établi.

Des réactions allergiques ou une hypersensibilité médicamenteuse, y compris l’urticaire, un bronchospasme, une éruption cutanée et un prurit, ont été rapportées par des patients ayant reçu du dabigatran etexilate. De rares cas de réactions anaphylactiques ont également été rapportés.

Pour obtenir le guide thérapeutique complet, prière de consulter la monographie du produit.

Chez les patients atteints de fi brillation auriculaire, Pradax a démontré :

Comme c’est le cas avec tous les anticoagulants, PRADAX devrait être utilisé avec précaution lorsqu’il existe un risque plus élevé de saignement. Un saignement peut survenir n’importe où dans l’organisme durant le traitement par PRADAX. En cas de saignement grave, le traitement par PRADAX doit être interrompu et la source du saignement rapidement recherchée.

Les patients présentant un risque plus élevé de saignement devraient faire l’objet de surveillance clinique étroite. Un test de la coagulation, tel que le test du temps de céphaline activée peut être utile pour identifi er les patients qui présentent un risque plus élevé de saignement dû à une exposition excessive au dabigatran. *Étude de non-infériorité à répartition aléatoire menée auprès de 18 113 patients atteints de FA prédisposés à l’AVC. Les patients recevaient soit le dabigatran à 110 mg bid ou à 150 mg bid (groupe à l’insu) ou des doses ajustées de warfarine (groupe ouvert). †AVC ou embolie systémique : dabigatran à 150 mg bid (n = 6 076, nombre d’événements = 134) par rapport à la warfarine (n = 6 022, nombre d’événements = 202).¥AVC ischémique : dabigatran à 150 mg bid (n = 6 076, nombre d’événements = 103) par rapport à la warfarine (n = 6 022, nombre d’événements = 134). ‡L’hémorragie intracrânienne comprend les AVC hémorragiques attestés et les hémorragies sous-arachnoïdiennes et/ou sous-durales. §Hémorragie intracrânienne : dabigatran à 150 mg bid (n = 6 076, nombre d’événements = 38) par rapport à la warfarine (n = 6 022, nombre d’événements = 90). ¢L’hémorragie menaçant la vie était une sous-catégorie de l’hémorragie majeure et incluait : hémorragie mortelle, hémorragie intracrânienne symptomatique, hémorragie avec baisse du taux d’hémoglobine d’au moins 50 g par litre ou hémorragie nécessitant la transfusion d’au moins 4 unités de sang ou d’agents inotropes ou nécessitant une chirurgie. £Hémorragie majeure menaçant la vie : dabigatran à 150 mg bid (n = 6 076, nombre d’événements = 179) par rapport à la warfarine (n = 6 022, nombre d’événements = 218).

BIPRA111328F Visitez Pradax.ca

PrPRADAX® à 150 mg bid Indiqué pour la prévention de l’accident vasculaire cérébral (AVC) et de l’embolie systémique chez les patients atteints de fi brillation auriculaire (FA) pouvant recevoir une anticoagulothérapie1.

Est-ce que Pradax à 150 mg bid est une option thérapeutique pour ces patients atteints de FA? Patients à risque élevé

Pour toute question au sujet de Pradax, composez le 1-855-PRADAX5 (772-3295).

PATIENTS ATTEINTS DE FA PRADAX À VOSPRESCRIVEZ

PRÉDISPOSÉS À L’AVC

Réduction du risque d’AVC ou d’embolie systémique de 35 %

par rapport à la warfarine1*†

Dabigatran à 150 mg bid (1,1 %/an) par rapport à la warfarine (1,7 %/an), p=0,0001.

Réduction du risque d’AVC ischémique de 25 % par rapport à la warfarine1*¥


Risque d’hémorragie intracrânienne‡ moins élevé de 59 %

par rapport à la warfarine1*§

Dabigatran à 150 mg bid (0,3 %/an) par rapport à la warfarine (0,8 %/an), p<0,0001.

Risque d’hémorragie menaçant la vie¢ moins élevé de 20 %

par rapport à la warfarine1*£


Aucune surveillance du RIN1

Références : 1. Monographie de Pradax. Boehringer Ingelheim (Canada) Ltée, 27 janvier 2012. 2. Skanes Allan C et al. Focused 2012 Update of the Canadian Cardiovascular Society Atrial Fibrillation Guidelines: recommendations for stroke prevention and rate/rhythm control. Can J Cardiol 2012;28:125-136.

Pradax® est une marque déposée utilisée sous licence par Boehringer Ingelheim (Canada) Ltée.

B 1-3 2 11:51 AM

WITH PRADAXPREVENT STROKE HELP

AND SYSTEMIC EMBOLISM

See prescribing summary on page

PrPRADAX® 150 mg BID INDICATED FOR THE PREVENTION OF STROKE AND SYSTEMIC EMBOLISM IN

PATIENTS WITH ATRIAL FIBRILLATION, IN WHOM ANTICOAGULATION IS APPROPRIATE.1

PrPRADAX®

carbamazepine are also expected to reduce dabigatran plasma concentrations and should be co-administered with caution.

The most common adverse reactions observed in 1% of PRADAX 150 mg BID patients and 110 mg BID patients was anemia (1.6%, 1.2%), epistaxis (1.1%, 1.1%), gastrointestinal hemorrhage (4.6%, 3.3%), urogenital hemorrhage (1.4%, 1.1%), abdominal pain (2.2%, 2.3%), diarrhea (1.2%, 1.3%), dyspepsia (3.9%, 4.2%) and nausea (1.2%, 1.0%), respectively. Gastrointestinal adverse reactions occurred more often with dabigatran etexilate than warfarin. These were related to dyspepsia (including upper abdominal pain, abdominal pain, abdominal discomfort, epigastric discomfort) or gastritis-like symptoms (including GERD, esophagitis, erosive gastritis, gastric hemorrhage, hemorrhagic gastritis, hemorrhagic erosive gastritis and gastrointestinal ulcer). Gastrointestinal hemorrhage occurred at a higher frequency with PRADAX 150 mg BID and 110 mg BID (4.6%, 3.3%, respectively) compared to warfarin (2.6%). The underlying mechanism of the increased rate of GI bleeding has not been established.

Allergic reactions or drug hypersensitivity including urticaria, bronchospasm, rash and pruritus have been reported in patients who received dabigatran etexilate. Rare cases of anaphylactic reactions have also been reported.

Patients at an increased risk of bleeding should be closely monitored clinically. A coagulation test, such as aPTT may help to identify patients with an increased bleeding risk caused by excessive dabigatran exposure.

For complete prescribing information, please refer to the Product Monograph.* A randomized non-inferiority trial of 18,113 AF patients at risk of stroke. Patients received dabigatran 110 mg BID or 150 mg BID (blinded arm) or adjusted doses of warfarin (unblinded arm).

† Stroke or systemic embolism: dabigatran 150 mg BID (n=6076, no. of events=134) vs. warfarin (n=6022, no. of events=202).

‡ Intracranial bleeding includes adjudicated hemorrhagic stroke, subarachnoid, and/or subdural bleeding.

§ Intracranial bleeding: dabigatran 150 mg BID (no. of events=38) vs. warfarin (no. of events=90).

References: 1. Pradax Product Monograph. Boehringer Ingelheim (Canada) Ltd., 06/13/11. 2. Connolly SJ et al. Dabigatran versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med. 2009;361:1139–1151. 3. Connolly SJ et al. Newly Identifi ed Events in the RE-LY Trial. N Engl J Med. 2010;363:1875-1876 supp appendix. 4. Liste de médicaments publiée par la Régie de l’assurance maladie du Québec. April 2011.Pradax® is a registered trademark used under license by Boehringer Ingelheim (Canada) Ltd.

PRADAX (dabigatran etexilate) is indicated for the prevention of stroke and systemic embolism in patients with atrial fi brillation, in whom anticoagulation is appropriate.

PRADAX is contraindicated in patients with: severe renal impairment (CrCL <30 mL/min); hemorrhagic manifestations, bleeding diathesis, or patients with spontaneous or pharmacological impairment of hemostasis; lesions at risk of clinically significant bleeding, e.g. extensive cerebral infarction (hemorrhagic or ischemic) within the last 6 months, active peptic ulcer disease with recent bleeding; concomitant treatment with strong P-glycoprotein (P-gp) inhibitors, i.e. oral ketoconazole, and with known hypersensitivity to dabigatran, dabigatran etexilate or to any ingredient in the formulation or component of the container.

Bleeding is the most relevant side effect of PRADAX; bleeding of any type or severity occurred in long-term treatment in 16.5% of patients with atrial fi brillation treated for the prevention of stroke and systemic embolism. As with all anticoagulants, PRADAX should be used with caution in circumstances associated with an increased risk of bleeding. Bleeding can occur at any site during therapy with PRADAX. An unexplained fall in hemoglobin and/or hematocrit or blood pressure should lead to a search for a bleeding site. Patients at high risk of bleeding should not be prescribed PRADAX. Close clinical surveillance (looking for signs of bleeding or anemia) is recommended throughout the treatment period, especially if risk factors are combined. Should severe bleeding occur, treatment with PRADAX must be discontinued and the source of bleeding investigated promptly. Patients who develop acute renal failure must discontinue PRADAX. In patients who

are bleeding, an aPTT test may be useful to assist in determining an excess of anticoagulant activity, despite its limited sensitivity. An aPTT >80 sec at trough, i.e. when the next dose is due, is associated with a higher risk of bleeding.

Agents that may enhance the risk of hemorrhage should not be administered concomitantly with PRADAX, or, if necessary, should only be administered with caution. Treatments that should NOT be administered concomitantly with PRADAX due to increase in bleeding risk include: unfractionated heparin and heparin derivatives, low molecular weight heparins (LMWH), fondaparinux, bivalirudin, thrombolytic agents, GPIIb/IIIa receptor antagonists, ticlopidine, sulfinpyrazone and vitamin K antagonists such as warfarin. The concomitant use of PRADAX with the following treatments has not been studied and may increase the risk of bleeding: rivaroxaban, prasugrel and the strong P-gp inhibitors dronedarone, itraconazole, tacrolimus, cyclosporine, ritonavir, tipranavir, nelfinavir and saquinavir. Unfractionated heparin may be administered at doses necessary to maintain a patent central venous or arterial catheter. In patients with atrial fi brillation treated for the prevention of stroke and systemic embolism, the co-administration of oral anti-platelet (including ASA and clopidogrel) and NSAID therapies increases the risk of bleeding by about two-fold. If necessary, co-administration of low-dose ASA, i.e. 100 mg daily with PRADAX may be considered for other indications than stroke prevention in atrial fi brillation. The concomitant use of PRADAX with the strong P-gp inducer, rifampicin, reduces dabigatran plasma concentrations. Other P-gp inducers such as St. John’s Wort or

For patients with atrial fi brillation, PRADAX demonstrated:

reduced risk of stroke or systemic embolism vs. warfarin1-3*†

Dabigatran 150 mg BID (1.1%/yr) vs. warfarin (1.7%/yr), p=0.0001.

reduced risk of intracranial bleeding‡ vs. warfarin1-3*§

Dabigatran 150 mg BID (0.3%/yr) vs. warfarin (0.8%/yr), p<0.0001.

No INR monitoring or dose titration1

Covered by the

Liste de médicaments

du Québec with Exception Drug Status4

12:56 PM

Pr Pradax® for Stroke and Systemic Embolism Prevention in Atrial Fibrillation

A guide to support the use of Pradax.

1 0 2:10 PM

AVOID BRAND NAME CONFUSION

BETWEEN PrPRADAX®

AND PrPLAVIX®

The Pradax® and Plavix® names, verbally and by script, have been mistaken for one another. These mix-ups have been associated with similarities in orthographics, phonetics and strength.

To reduce the potential for name confusion errors, healthcare professionals are encouraged to include the generic name dabigatran when referring to Pradax®, or the name clopidogrel when referring to Plavix®. Spelling the name of the medication for verbal prescriptions is also suggested.

Pradax® is a registered trademark used under license by Boehringer Ingelheim (Canada) Ltd. Plavix® is a registered trademark used under license by Sanofi -aventis Canada Inc.

BIPRA121200E

Pradax at Grip Limited


GOÛT LÉGÈREMENTSUCRÉ, ENTIÈREMENT

NATUREL

100 CALORIES

NOUVEAU

UN GOÛT SUBLIME AVEC UNE NOUVELLE TOUCHE SPÉCIALE.

EN FAIT, 2 NOUVELLES TOUCHES.

VEUILLEZ CONSOMMER AVEC MODÉRATION.

BACARDI, LE SIGNE DE LA CHAUVE-SOURIS ET BREEZER SONT DES MARQUES DÉPOSÉES

DE BACARDI & COMPANY LIMITED.

BACARDI ET WILD VINES VOUS RASSEMBLENT À OSHEAGA !POUR PARTICIPER, VISITEZ : WWW.OSHEAGAPARTY.CA – TU PEUX

UN DES FORFAITS 3 JOURS POUR 4 PERSONNES D’UNE VALEUR DE 870 $.GAGNER

18 ans et plus. Aucun achat requis. Le concours débute à 00 h 01 m (HAE) le 27 mai 2012 et prendra fi n à 23 h 59 m (HAE) le 21 juillet 2012. La personne gagnante du grand prix sera choisie par tirage au sort le 23 juillet 2012. Pour obtenir les règlements complets du concours et pour y participer, visitez www.osheagaparty.ca. VEUILLEZ CONSOMMER AVEC MODÉRATION. BACARDI ET LE SIGNE DE LA CHAUVE-SOURIS SONT DES MARQUES DÉPOSÉES DE BACARDI & COMPANY LIMITED.

FACEBOOK.COM/BACARDI

RABAIS INSTANTANÉPrésentez ce coupon à la caisse et obtenez un rabais de

VEUILLEZ CONSOMMER AVEC MODÉRATION. BACARDI, LE SIGNE DE LA CHAUVE-SOURIS ET BREEZER SONT DES MARQUES DÉPOSÉES DE BACARDI & COMPANY LIMITED.

2 $Bacardi Breezer Ananas 4x330 mL

TAXES INCLUSES



1 $Bacardi Breezer Ananas 100 Cal 4x330 mL

TAXES INCLUSES



Bacardi Superior & Cola 473 mLRABAIS INSTANTANÉPrésentez ce coupon à la caisse et obtenez un rabais de


Wild Vines Framboise 750 mLRABAIS INSTANTANÉPrésentez ce coupon à la caisse et obtenez un rabais de


2 $Bacardi Superior 750 mL

TAXES INCLUSES



3 $Bacardi Superior 1,14 L

TAXES INCLUSES



5 $Bacardi Superior 1,75 L

TAXES INCLUSES



2 $Bacardi Gold 750 mL

TAXES INCLUSES



2 $Bacardi Breezer Spritzer 4x330 mL

TAXES INCLUSES



1 $Bacardi Breezer Orange 4x330 mL

TAXES INCLUSES



Wild Vines Fraise 750 mLRABAIS INSTANTANÉPrésentez ce coupon à la caisse et obtenez un rabais de


Wild Vines Mûre 750 mLRABAIS INSTANTANÉPrésentez ce coupon à la caisse et obtenez un rabais de


2 $Bacardi8 750 mL

TAXES INCLUSES



2 $Bacardi Oakheart 750 mL

TAXES INCLUSES



2 $Bacardi Black 750 mL

TAXES INCLUSES



3 $Bacardi Gold 1,14 L

TAXES INCLUSES

0,75 $TAXES INCLUSES




1-2 0 10:50 AM

BUNDLE YOURSUMMER SALE

Flights Vacation Packages Hotels Cars Rail Cruises ToursHome Activities MobileDEALS

Add saving up to 40% to your travel itinerary. Save up to 40%* on your stay when you bundle your flight and hotel together. That’s enough savings to see more sites, take more tours or check out more restaurants on your summer getaway.

© 2012 Expedia, Inc. All rights reserved. Expedia, Expedia.ca, and the Airplane logos are registered trademarks, or trademarks, of Expedia, Inc. in the U.S. and/or other countries. Ticket fulfillment services provided by Tour East Holidays (Canada) Inc., 15 Kern Road, Suite 9, Toronto, Ontario M3B 1S9. TICO Registration No.: 50015827 and Tour East Holiday (Canada) Inc., 2000 Peel Street, Suite 735 Montréal, QC H3A 2W5. Quebec License No. 702246. *Discount limited to hotel portion of build-your-own (flight + hotel) bookings only (off Expedia.ca prices) purchased by July 2/12 for travel between June 5/12 and Sept 30/12. Some conditions apply. Only valid on select Bundle Your Summer Sale cities and properties. Offer subject to change or cancellation without notice. See expedia.ca for full details.

BisacodylBi d l

Tablets

Gentle, predictableovernight relief

Convenient, small and easy-to-swallow

Special coating

Suppositories

Gentle and predictable relief in less than an hour

Gentle, predictable relief with Tablets and SuppositoriesGentle, predictable relief with Tablets and Suppositories

The Dulcolax RangeNEW LOOK

SAME GREATPRODUCT

dulcolax.caDulcolax® may not be right for you, always read and follow the label.

UPC PRODUCT DESCRIPTION SIZE CASE PACK INNER PACK LIST PRICE

0 58341 01511 5 Dulcolax® Tablets, 5 mg 10 tabs 54 9 $1.860 58341 01513 9 Dulcolax® Tablets, 5 mg 30 tabs 54 9 $4.750 58341 01514 6 Dulcolax® Tablets, 5 mg 60 tabs 54 9 $8.570 58341 02001 0 Dulcolax® Tablets, 5 mg 100 tabs 144 12 $12.080 58341 01521 4 Dulcolax® Suppositories, 10 mg 3 supps 90 6 $3.330 58341 01523 8 Dulcolax® Suppositories, 10 mg 6 supps 90 6 $5.500 58341 01525 2 Dulcolax® Suppositories, 10 mg 100 supps 24 1 $56.07

5:57 PM

Certified General Accountants see more than numbers. When it comes to leadership,

we see the impact and opportunity behind those numbers. That’s because, in this

fast changing economic climate, innovative leadership is seeing how numbers impact

our business – before they do.

CGA-more.org

Rich Harvey, CGA Hockey Finance Manager Bauer Canada

. 1 1 - - 3:03 PM

Certified General Accountants see mor

we see the impact and opportunity behind those numbers. That’

fast changing economic climate, innovative leadership is seeing how numbers impact

our business – befor

General Accountants see mor

e impact and opportunity behind those numbers. That’

ging economic climate, innovative leadership is seeing how numbers impact

e they do. ess – befor

e than numbers. When it comes to leadership, e mor

ty behind those numbers. That’

innovative leadership is seeing how numbers impact

When it comes to leadership,

s because, in this ers. That’

s seeing how numbers impact

ership,

his

mpact

eCGA-mor

ge.or

We see the pressures of a global economy.

L E A D E R S H I P | E F F I C I E N C Y | P R O D U C T I V I T Y | S U S T A I N A B I L I T Y | M A N A G I N G R I S K

Certifi ed General Accountants see the implications and opportunities of today’s global economy. Whether as an employee or trusted consultant, your CGA looks beyond the balance sheet to help every player on your team fi nd effi ciencies, create opportunity and maximize value. That’s because they’ve learned that in a global economy, success isn’t a moving target, it’s a moving market. To help you hit your mark, choose someone who sees the bigger picture. Choose a CGA.

cga-more.org

1 1 3:23 PM

Other projects at Grip Limited

G

S

INNER PACK LIST PRICE

0

The World’sThe World’s

OTC LaxativeOTC L axativeNo.1

Our commitment in 2012NEWNEW National TV Campaign.

Time to stock your shelves!

NEW LOOKSAME GREAT

PRODUCT

BisacodylBisacodyl

Verac i t y Cap i t a l I n c .


Integrated Facility Solutions, Inc.

��yyyy

��

yyyyyyyyy

��

�� yy

yy �y

R E G I O N A L M E D I C A L R E S E A R C H

R E C H E R C H E M É D I C A L E R É G I O N A L E

furniture design architecture

professional services

healthcare

financial

technology

leisure

fashion

Pavel is responsible for designing and implementing over 40 logos for corporate, manufacturing, pharmaceutical, retail and fashion clients.

The following pages showcase select work samples ranging from logo design and corporate brochures to marketing and advertising campaigns.


Which would you rather have, a cholesterol test or a final exam?For many, the first sign of heart disease is a heartattack. Did you know that one out of two adultCanadians is at risk of developing heart disease because they have high cholesterol? And that cardiovascular disease IS the leading cause of death in Canada?

High cholesterol is a major risk factor for heart disease but managing your cholesterol can be quite simple.

If any of these apply to you, cut this screening test out and ask your doctor about getting your cholesterol tested:

Woman 50 years or older

Man 40 years or older

Heart disease (angina, heart attack, coronary bypass, stroke,angioplasty)

Diabetes

Family history (mother, father, sister, brother or grandparent) of heart disease or high cholesterol

Two or more of the following:

• Overweight• Physically inactive• Smoker• High blood pressure

Call toll-free at 1-877-4-LOW-LDL(1-877-456-9535) or visitwww.makingtheconnection.ca and you will receive this free booklet describing the connection between cholesterol and heart disease.

The Canadian Diabetes Association has reviewed the “Making the Connection” program for its medical and scientificaccuracy. The Canadian Diabetes Association does not endorse the products of any pharmaceutical company. Sponsored by one of Canada’s research based pharmaceutical companies.

Use your Shopping Companion to

chart your low-cholesterol food

choices and recipe ingredients.

Keep this journal handy

for when you go grocery shopping.

Managing yourcholesterol

pharmaceutical

atorvastatine calciquecomprimés

EFFICACE POUR VISER JUSTE

Efficacité…Expérience…Études à l’appui, dansl’atteinte de la cible de


YOUR ANTIHYPERTENSIVE THERAPY SHOU LD BE AS DEPENDABLE AS THE SUNRISE

Prolonged & Sustained 24-Hour Blood Pressure Control▲ Provided similar efficacy in clinic [trough] blood pressure reduction to Norvasc* (amlodipine)1‡

▲ “…was also associated with a greater reduction in ambulatory blood pressure during the night-

time interval and during the last 4 hours of the dosing period” than Norvasc* (amlodipine)1

▲ MICARDIS® (40-80 mg) demonstrated at least similar efficacy to Vasotec® (5-20 mg)2,3ƒ

▲ Significantly more effective than Cozaar® 50 mg (losartan) in blood pressure reduction

18-24 hours post-dose4✪

Excellent Pharmacokinetic Profile▲ 24-hour half-life, longest of all AT1 receptor blockers3†§

▲ Fastest time to maximum plasma concentration3†§

▲ Trough to peak ratio 92-100% for 80 mg5,6

▲ 97% hepatic excretion3

Excellent Tolerability★

▲ Discontinuation rate due to adverse events was less with

MICARDIS® (2.8%) than with placebo (6.1%)3★

▲ Excellent drug interaction profile3#

▲ Not metabolized by cytochrome P450 isoenzymes3

Simple Dosing▲ 80 mg once-a-day starting and maintenance dose,

regardless of age, gender or renal status3

▲ No titration required3

▲ Can be taken with or without food3

FULL 24-HOUR PROTECTION, INCLUDINGTHE CRITICAL EARLY MORNING HOURS

HYPERTENSION NEVER TAKES TIME OFF...

NEITHER SHOULD YOURANTIHYPERTENSIVE

NEW

T E L M I S A R T A N 8 0 m g A T1 R E C E P T O R B L O C K E R

®

Pr

Antihypertensive protection day and night.

NEW

T E L M I S A R T A N 8 0 m g A T1 R E C E P T O R B L O C K E R

Pr

®

Co-promoted with

*TM Pfizer Products Inc., Pfizer Canada Inc., licensee. ® Trademark Merck & Co., Inc./Merck Frosst Canada Inc., licensed user. Cozaar® is a registered trademark of E.I. du Pont de Nemours and Company, Merck Frosst & Co., licensed user.

References: 1. Lacourcière Y, et al. A comparison of the efficacy and duration of action of the angiotensin II receptor blocker telmisartan to amlodipine. Blood Pressure Monitoring 1998;3(5):295-302. 2. Smith DHG, Neutel JM, Morgenstern P.Once-Daily Telmisartan Compared with Enalapril in the Treatment of Hypertension. Advances in Therapy 1998;16(4):229-240. 3. MICARDIS® Product Monograph, Boehringer Ingelheim (Canada) Ltd. August, 1999. 4. Mallion JM, Lacourcière Y.ABPM Comparison of the Antihypertensive Profiles of the Selective Angiotensin II Receptor Antagonists Telmisartan and Losartan in Patients with Mild-to-Moderate Hypertension. The Journal of Human Hypertension (In press). 5. Bakris G, et al.Clinical Efficacy and Safety Profiles of AT1 Receptor Antagonists. CVR&R 1999; February 1999:78-100. 6. Neutel JM, Smith DHG. Dose Response and Antihypertensive Efficacy of the AT1 Receptor Antagonist Telmisartan in Patients with Mild toModerate Hypertension. Advances in Therapy 1998;15(4):206-217.

MICARDIS® (telmisartan) is indicated for the treatment of mild to moderate hypertension.MICARDIS® may be used alone or in combination with thiazide diuretics.MICARDIS® should normally be used in those patients in whom treatment with diuretic or beta blocker was found ineffective or has been associated with unacceptable adverse effects. MICARDIS® can also be tried as an initial agent in those patients in whom the use of diuretics and/or beta blockers is contraindicated or in patients with medical conditions in which these drugs frequently cause serious adverse effects.If pregnancy is detected, MICARDIS® should be discontinued as soon as possible. In patients who are volume-depleted by diuretic therapy, dietary salt restrictions, dialysis, diarrhea or vomiting, symptomatic hypotension may occur after initiation of therapy with MICARDIS®.

‡ Results from 12-week double-blind phase, 40 mg MICARDIS® (n=73) and 5 mg Norvasc* (n=78), p<0.0001Similar reduction in DBP was observed over the 24-hour mean period. Results after 12 weeks monotherapy asmeasured by 24-hour ABPM with MICARDIS® (n=73; increased to 80 and 120 mg as necessary for patientswhose DBP remained >90 mmHg) and Norvasc* (n=78; titrated to 5 mg and titrated to 10 mg for patients whoseDBP remained >90 mmHg). p<0.05. The recommended dose of MICARDIS® is 80 mg once-daily, 120 mg providedno additional mean reduction in blood pressure.

ƒ There was similar reduction in DBP at weeks 1, 4 , and 8. MICARDIS® 80 mg (n=72), Vasotec® 20 mg (n=72),p=0.03 for DBP, p=0.01 for SBP.

✪ ABPM 18-24h post-dose period comparing Cozaar® 50 mg (n=50) and MICARDIS® 40 and 80 mg (n=52) at week6 of therapy p<0.05.

† From product monographs of valsartan, losartan, irbesartan, and candesartan. ★ The most common adverse events are headache, upper respiratory tract infection and dizziness.§ Comparative clinical significance is investigational. # Digoxin levels should be monitored when initiating, adjusting, or discontinuing MICARDIS®.

No initial dosing adjustment is necessary for elderly patients or for patients with renal impairment, but greater sensitivity in some older individuals cannot be ruled out. For patients with hepatic impairment, a starting dose of40 mg is recommended.

Notes

LIPITOR *: Hitting targets.

LIPITOR is an HMG-CoA reductase inhibitor (statin). LIPITOR is indicated as an adjunct to lifestyle changes, including diet, for the reduction of elevated total cholesterol, LDL-C, TG andapolipoprotein B in hyperlipidemic and dyslipidemic conditions (including primary hypercholesterolemia, combined [mixed] hyperlipidemia, dysbetalipoproteinemia, hypertriglyceridemiaand familial hypercholesterolemia) when response to diet and other non-pharmacological measures alone has been inadequate.LIPITOR also raises HDL-cholesterol and therefore lowers the LDL-C/HDL-C and Total-C/HDL-C ratios (Fredrickson Type IIa and IIb). These changes in HDL-C with HMG-CoA reductaseinhibitors should be considered as modest when compared to those observed in LDL-C and do not play a primary role in the lowering of LDL-C/HDL-C and Total-C/HDL-C ratios.See prescribing information for complete warnings, precautions, dosing and administration.LIPITOR is contraindicated: During pregnancy and lactation; active liver disease or unexplained persistent elevations of serum transaminases exceeding 3 times the upper limit of normal;hypersensitivity to any component of this medication.Lipid levels should be monitored periodically and, if necessary, the dose of LIPITOR adjusted based on target lipid levels recommended by guidelines.Caution should be exercised in severely hypercholesterolemic patients who are also renally impaired, elderly, or are concomitantly being administered digoxin or CYP 3A4 inhibitors.Liver function tests should be performed before the initiation of treatment, and periodically thereafter. Special attention should be paid to patients who develop elevated serum transaminaselevels, and in these patients measurements should be repeated promptly and then performed more frequently.The effects of atorvastatin-induced changes in lipoprotein levels, including reduction of serum cholesterol on cardiovascular morbidity, mortality, or total mortality have not been established.‡ A patient-year represents the total time of exposure to LIPITOR as defined by the sum of each patient time on LIPITOR.5

¥ The Atorvastatin Versus Revascularization Treatments (AVERT) study examined the effect of intensive lipid-lowering in patients with stable coronary artery disease and LDL-C at least 3.0mmol/L in patients referred for percutaneous transluminal coronary angioplasty (PTCA). Patients were randomized for 18 months to LIPITOR 80 mg daily or to PTCA with usual medicalcare which could include lipid metabolism regulators. The results of the AVERT study should be considered as exploratory since several limitations may affect its design and conduct. Inthe medical-treated group with LIPITOR there was a trend for a reduced incidence of ischemic events and a delayed time to first ischemic event. The results also suggest that intensivetreatment to target LDL-C levels with LIPITOR is additive and complementary to angioplasty and would benefit patients referred for this procedure.1

39-60%1†

LDL -C TG

25-56%(type IV)1†

29-44%TC/HDL-C

(type IIa and IIb)1†

Clinicalresearchprogram4

EFFICACY ➣ † A powerful demonstrated effect across key lipid parameters1

EXPERIENCE ➣ More than 40 million patient-years of experience2‡

EVIDENCE ➣ Demonstrated delayed time to first ischemicevent in stable CAD patients (n=164, p=0.03)3¥

LIPITOR has a leading edge clinical research program exploringnew areas that may extend beyond lipid control4

Aiming beyond.Aiming beyond.

pharmaceutical

Because the early morning hours are critical...

Full 24-Hour Protection from BP Surges,Including the Critical Early Morning Hours

Because the early morning hours are critical...

Full 24-Hour Protection from BP Surges,Including the Critical Early Morning Hours

JSAI

Training marketers to be marketects

JEFFREY SIMBROW ASSOCIATES INC.

JSAI


JSAI Introduction

Jeffrey Simbrow Associates Inc. (JSAI) offers a curriculum of interactive skill-basedseminars designed to enhance the competencies of marketing executives to become moreeffective brand builders. Our training seminars, utilizing best practices, are provided inmarketing and brand planning, positioning and communication strategy development,advertising development, research, promotion and media planning.

JSAI’s internationally acclaimed training seminars have been executed for companies aroundthe world for industries as diverse as brewing, pharmaceutical, financial services,entertainment, professional sports, food and packaged goods. Our clients include leading

companies such as Interbrew, Pepsi QuakerTropicana Gatorade Canada, Pfizer, Schering, EliLilly, Corus Entertainment, Alliance Atlantis, TorontoBlue Jays, Toronto Dominion Bank… To date, wehave conducted more than 100 programs throughoutthe world including Toronto, Montreal, New York,San Francisco, Los Angeles, London, Tokyo, Seoul,Brussels, Budapest, Amman, Singapore, Bangkok,Rome, Paris, Helsinki and other major cities. Wehave trained more than 2,500 marketing managersworldwide to become “marketects”.

Who Should Attend

JSAI training seminars provide an unparalleled idea-sharing and network opportunity fora select group of senior managers. Typical titles include Chief Marketing Officer, VicePresident Marketing, Marketing Director, Sales Director, Brand Manager, Assistant BrandManager, Sales Manager, Marketing Research Manager, Advertising Agency Consultant, etc.

3

JSAI Introduction 3

Overall Objectives 4

JSAI Strengths 5

Training Programs 6

Speaker Bio 14

Case Studies 15

Client Testimonials 16

Contact Information 18

2

13

Media Planning [Code 006]Objectives:

To become familiar with/understand the language of media

To understand the basic principles underlying the construction of a media plan inorder to:

• Challenge/suggest alternatives to agency media recommendations

• Defend/explain media choices

Contents:

Key Media Terms

Strength and Weakness of Media Classes

The Media Planning Process

• Information Required

• Media Objectives

• Media Strategies

• Media Tactics

• Media Tools – Research

• What the Media Plan Should Look Like

– Plan Evaluation Checklist

Plan Execution

• Market Dynamics Media Classes

12 JSAI

marketing training


Prepared by Jeffrey Simbrow Associates Inc.

USA June 2002

Interbrew Promotion Training Program


Prepared by Jef f rey S imbrow Assoc iates Inc.

M A R K E T I N G T R A I N I N G P R O G R A MM A R K E T I N G T R A I N I N G P R O G R A M




marketing training


All About

The Sharp LCD TV Guide

Top consumermyths about LCD

technology

Top consumer m

yths about LCD

technology

Wide Viewing AngleThe AQUOS provides a wide viewing angle of 170 degrees, bothhorizontally andvertically, allowing youto view the screen clearlyfrom virtually anywherein a room, regardless of what angle the TV or viewer is positioned in.

Clear Reproduction of Fast Moving Video ClipsAnother benefit that Sharp ASV technology brings to LCD is Sharp’sproprietary Quick Shoot component. Quick Shoot improves the quality ofmoving scenes on liquid crystal panels by achieving exceedingly highresponse times resulting in unsurpassed picture playback and realism.

High Performance Liquid Crystal Control Sharp’s High Performance LC control technology is a key benefit of the AQUOS line-up. The liquid-crystal displays (LCDs) in use today relyon picture elements, or pixels, formed by liquid-crystal (LC) cells thatchange the polarization direction of light passing through them inresponse to an electrical voltage. As the polarization direction changes, more or less of the light is able to pass through a polarizing layer on the face of the display. Change thevoltage, and the amount of light is changed. Sharp ASV technology has ahigh level of control over individual pixels allowing for the reproductionof thicker and darker contrast enabled blacks.

Best in Class Picture QualityIt’s not enough to build a bigger panel. As the panels become larger the need for a higher resolution panel becomes even more evident. For example, the Sharp LC37G4U has a unique High-Definition LCD Panelwhich packs over 3.1 million pixels in a 37" display.Compared to a plasma TV of the same screen size, this LCD panel has 30 per cent more horizontal pixels delivering a highly precise, super-realistic picture.

All About AQUOS: The Sharp LCD TV Guide

INTRODUCTION TO AQUOS 3

Horizontal 170°

Vertical 170°

Conventional LCD Advanced Super View with Quick Shoot

technology

The Canadian Pharmaceutical Marketing Program

Learning to build strongerhealthcare brands

• Improve profitability

• Gain market advantage

• Maximize value through the entire product lifecycle

www.humber.ca/healthindustry


The Canadian Pharmaceutical Marketing Program

Learning to build stronger healthcare brands

4-day Professional Development Program

Developed for the industry, by the industry, the CanadianPharmaceutical Marketing Program is a unique, practicalcareer development program that approaches marketingfrom a healthcare perspective. Over the course of fourintensive full-day sessions, participants will learn bestpractices for designing and implementing a successful brandstrategy in today’s dynamic pharmaceutical marketplace.

New product managers, associate product managers, andothers involved in planning and implementing marketingstrategies will walk away with an actionable framework that can be immediately applied to:

• Improve profitability

• Gain market advantage

• Maximize value through the entire product lifecycle

• Largest 4-year nursing degree program offered exclusively at a college

• Focus on primary health care & advocacy

• Outstanding faculty with professional practice & teaching experience

• Exceptional nursing simulation & anatomy labs

• Full and part-time practical nursing diploma

humber.ca/healthsciences • 416.675.5000

Congratulations to the first graduates of the UNB-Humber Bachelor of Nursing Degree

(June 2005)

• Largest nursing program in Ontario

• D iverse full-time and part-time programs

• Academic and clinical excellence

• Outstanding faculty and teaching excellence

• Modern, high-tech facilities

humber.ca/healthsciences 416.675.5000

Diplomas • Certificates • Bachelor’s Degree in Nursing Postgraduate Programs • Continuing Education

education


N

Enclosed Area CoverageEnc losed Area CoverageCHANEXCOMCHANEXCOM

N owhere are coverage problems more

apparent than in enclosed areas. Anyone

who has t r ied to use a mobi le radio or

cellular phone in buildings, tunnels or

subways knows the feeling.

Futurecom’s CHANEXCOM is a system

solut ion speci f ica l ly designed to solve

e n c l o s e d - a r e a c o v e r a g e p r o b l e m s .

I t p r o v i d e s t h e n e c e s s a r y

equ ipment fo r o f f -a i r s igna l

acquisition and enclosed area

RF distribution. It assures seam-

less integration of external and

internal coverage areas.

CHANEXCOM Channel Mod-

ules (CMD) ensure that only wanted

channels are allowed into coverage

extension areas, minimizing possi-

b le i n te rmod and in te r fe rence

problems. Channel Modules are

high specification, channel-selec-

tive repeaters capable of handling

digital and analog signals.

CHANEXCOM Channel Modules

can be programmed to work on-

channel or as frequency translators.

They are typically used to process

signals off-air at a head-end site. Signals can

then be distributed within the extended cov-

erage areas by conventional coaxial cables,

or over longer distances by f iber optics.

Distributed antennas or leaky coax cable

a re used t o r ad i a te t he s i gna l s i n t he

enclosed areas.

LA3B Tri-band Line Amplifiers are used

to compensate for signal losses over long

cable runs. When equipped with an option-

al AGC board they become smart, remotely

controlled devices.

CHANEXCOM supports VHF,

UHF, and 800/900 MHz fre-

q u e n c y b a n d s a n d c a n b e

equipped for remote monitoring and

control operation. This allows all

remote device settings to be opti-

mized from one central location

and provides for alarm and fail-

safe reconfiguration functionality.

CHANEXCOM Digs In

Futurecom’s CHANEXCOM enclosed

area coverage solutions have been

proven in the most demanding envi-

r o n m e n t s , i n c l u d i n g s u b w a y

systems in Toronto, New York City

and Los Angeles, Toronto’s “Under-

ground City” and Major Shopping

Malls and Office Tower Complexes

throughout the world.

CHANEXCOM is recognized among Public

Safety Agencies as the mission critical cov-

erage extension solution.

CHANEXCOM

FIBER OPTICBACKBONE

LA3B

CHANEXCOM

FIBER OPTICBACKBONE

LA3B

LA3BLA3B

LA3B

LA3B

LA3B

LA3B

PProviding high-quality portable radio cover-

age in wide-area systems and high-density

urban environments is one of the greatest chal-

lenges facing today’s radio system designers.

Their task becomes even more demanding when

additional factors such as cost, reliability, and

shortage of spectrum become part of the equa-

tion. Life would be much easier for these

hard-pressed system designers if only high qual-

ity portable coverage could be provided from

systems designed for mobile grade coverage.

F u t u r e c o m ’s M O B E X C O M Ve h i c u l a r

Repeater System (VRS) is one solution that can

solve some of the system designers’ portable

coverage problems.

M O B E X C O M p r o -

vides portable grade

coverage in systems

designed for mobile

c o v e r a g e . W h e n

mounted in a vehicle

and integrated with the system mobile i t

extends system coverage for personnel oper-

ating with portables.

MOBEXCOM can be seen as a Trunking

Gateway between a trunking and a conven-

tional system. The Trunking Gateway operates

like a trunking radio on the system side and

as a conventional radio on the local portable

side. It receives group and private calls and

retransmits them to the portable radio. The

portable radio calls are converted into the

group calls and retransmitted to the system.

The Gateway can be configured for in-band

or cross-band applications. The in-band con-

figuration is particularly beneficial as the same

portable radio can be used for communica-

tions directly with the system or via the VRS.

Loca l Area CoverageLoca l Area CoverageMOBEXCOMMOBEXCOM

Going from system to local coverage requires

only a change of channel. The Trunking Gate-

way is fully integrated with the trunking radio

and controlled by the mobile control head. It

also supports all important trunking system fea-

tures such as “go ahead” tones, group/private

calls and portable emergency transmissions.

The Trunking Gateway in a mobile appli-

cation provides portable radio coverage in

systems designed for mobile coverage. In a

fixed application it provides a cost effective

in-building coverage extension, requiring only

a single-channel distribution system that is far

less costly to implement than a multi-channel

design. As the Trunk-

ing Gateway operates

o n a d i f f e r e n t f r e -

q u e n c y f r o m t h e

system channels, high

system gains of up to

1 6 0 d B c a n b e

achieved without risking system lockup due to

the insufficient antenna isolation or high noise

floor problems that can be experienced with

BDA based solutions. In addition, it offers high

sensitivity and output power that makes the dis-

tribution system implementation very easy.

MOBEXCOM is compatible with major

t runking systems inc luding SMARTNET™

and EDACS™.

MOBEXCOM on the Move

Futurecom’s MOBEXCOM Vehicular Repeater

Systems are used by major police, ambulance

and fire agencies across North America. Their

robust construction and high specification make

them the only solution for these demanding

and lifesaving public safety applications.

WW ide-area systems provide RF coverage

across cities, provinces, states or countries.

Reliable wide-area coverage has a number

of obvious benefits:

• For Private Mobile Radio networkoperators it means higher system loading, which translates into higher air-time revenue.

• For public-safety radio systems such as police, ambulance or fire, it meansimproved safety, for both the public and service personnel.

• For utility companies, it meansmore efficient operations andlower operating costs.

The obvious way to improve

wide-area coverage is

to expand the system

infrastructure. How-

ever, there are two

fundamental drawbacks to

this approach: high cost and

limited spectrum availability.

Futurecom Systems Group Inc. pro-

vides an economical and efficient way to

deal with difficult coverage situations.

Our MULTEXCOM site extenders, in VHF, UHF,

800 and 900 MHz frequency bands, pro-

vide a reliable and cost-effective RF coverage

extension for remote communities, highways

or hilly terrain.

Futurecom MULTEXCOM site extenders

allow backbone coverage to be increased

wi thout spending mi l l ions of dol lars on

expanding network infrastructures. MULTEX-

COM site extenders are fully transparent,

system and protocol independent, and can

be used in analog or digital systems for voice

or data.

SaskTel Selects MULTEXCOM 800

SaskTel Mobility, a division of SaskTel, a

crown corporation owned by the Province of

Saskatchewan, chose Futurecom

MULTEXCOM 8 0 0 t o s o l v e a

unique challenge of providing

instant and reliable radio com-

munications to a small population

spread across a vast

prairie province.

Simply expanding

t h e m a i n n e t w o r k

infrastructure would have

been prohibitively expensive,

requiring additional site equip-

ment, as wel l as the expansion of

multi-site switches and backhaul facilities.

SaskTel chose to base i ts F leetNet

8 0 0 o n E r i c s s o n ’ s E D A C S® t r u n k e d

system. Today FleetNet 800 is the largest

private radio network in the world, providing

radio coverage over 400,000 sq. km. Fleet-

N e t 8 0 0 o p e r a t e s w i t h m o r e t h a n

160 RF s i tes , a lmost ha l f o f wh ich are

Futurecom MULTEXCOM 800 sites.

Wide Area CoverageWide Area CoverageMULTEXCOMMULTEXCOM

SITEXCOM – Frequency Translating Repeater SITEXCOM Technical Highlights

Any site can be used as a donor. As shown in the diagram, the SITEXCOM receives downlink frequency F2 from the donor

site and translates it to frequency F4. Terminals receive frequency F4 and respond on F3. The SITEXCOM receives uplink

frequency F3 and translates it to F1. As a result the donor site sees its terminals operating on F1/F2. The SITEXCOM site

is transparent to both the donor and the network. Terminals see the SITEXCOM site as just another base station which they

can freely roam to. Thanks to its high sensitivity and high output power the SITEXCOM can dramatically increase the

donor’s coverage area.

SITEXCOM Applications

Boosting revenue and cutting costs is a universal recipe for improving profitability. In the case of wireless

network operators, boosting revenue comes from increasing the number of subscribers and enlarging the access area.

Cutting costs means doing it inexpensively. Multiplying the number of base stations may be prohibitively expensive and

ineffective in many low density areas.

Frequency Translating Repeater (SITEXCOM) is the network operator’s dream-come-true. It extends RF

coverage at a much lower cost than base stations and is ideal for large, low congestion areas, coverage gaps (valleys,

cliffs etc.), highways, buildings, and underground.

SITEXCOM

COVERAGE GAPS

SITEXCOM

WIDE AREACOVERAGE

SITEXCOM

IN BUILDINGCOVERAGE

T1 T1 T1

SITEXCOM

HIGHWAY COVERAGE

DONOR

DONOR

DONORDONOR

LOCAL SWITCH

DONOR

DONOR

Highly modular construction

Easy “rear door” installation and access

Stainless steel padlockable latches

Channel Selective• Extends only desired channels. • Does not create simulcast effects. • Does not extend

competition’s channels. • Does not create or propagate

intermod products.

High Sensitivity/High Power• Provides good coverage.

Protocol Transparent• All the donor’s present and future

site features are available in theextended coverage area.

Wireless Interface• Does not require any network

expansion or telephone line connections.

Frequency Translating• Does not create simulcast effects

on the donor’s channel. • Can realize high system gain

(up to 163 dB).

On Channel (option)• Uses the same channel as

a donor site. • Ideal for applications where

simulcast is not a problem (e.g. in buildings, underground etc.).

Factory Calibrated. • Easy “no equipment” setup • Only a laptop is needed

to setup a site.

Software Controlled• Easy to reconfigure in the field.

Energy Efficient• No fans needed. • Efficient battery backup.• Low hydro bills.

Highly Modular• Easy to service and maintain.

Wireless Modem Interface (option)• Full remote alarm reporting.• Full remote programming.• Full remote monitoring.

Double Door Cabinet• Easy two stage installation.

Small Size, Weatherized Enclosure• Pole or roof installable. • Low site acquisition cost.

F1

F2

F1

F2

F3

F4

F3

F4

RF coverage by design1-800-701-9180

broad-band amplifiers vehicular repeaters channel-selectiverepeaters

technology

Ve

rac

ity

Ca

pit

al

Inc

.

Factors Favouring an Investment in the Partnership

Strong Performance

• Year-to date (as of October 15, 2003), the Partnership has gained17.7% net of all fees and expenses. On a trailing twelve-month basis,the Partnership has gained approximately 16.8% net of all fees andexpenses. These gains were achieved with considerably lower volatilitythan the overall equity markets.

Experienced Management

• Both Murray McDonald and Gregory Misztela, Managing Directors of the General Partner, have considerable senior level experience inmanaging alternative strategy equity pools and in investment research,as well as over 30 years of combined experience in the financialservices industry. Mr.McDonald has managed hedge funds forapproximately ten years and generated average annual returns in excess of 16%.

3


Scotia Plaza • 40 King St. W., Suite 4900 • Toronto, ON M5H 4A2 416.777.6749 • 416.777.6784 Fax

Verac i t y Cap i ta l I nc .

K. Murray McDonaldManaging Director

[email protected]

Scotia Plaza40 King St. W., Suite 4900Toronto, ON M5H 4A2416.777.6749 416.777.6784 Fax

Verac i t y Cap i ta l I nc .

Verac i t y Cap i ta l Inc .

Scotia Plaza • 40 King St. W., Suite 4900 • Toronto, ON M5H 4A2

Ve

rac

ity

Ca

pit

al

Inc

.

Key Terms of the Offering cont’d

Performance Fee

The General Partner is entitled to an annual performance fee equal to20% of any increase in the net asset value of the units during eachcalendar year.

Distribution of Income

Distributions may be made at the discretion of the General Partner.

Fiscal Year End

December 31 each year

Redemptions

Commencing June 30, 2003, provided the Limited Partner has held hisor her units for at least one year, units may be redeemed once a year on thirty (30) days’ prior written notice. Limited partners may requestredemption at other times, but acceptance of such request is in thediscretion of the General Partner.

8

Veracity Capital Partners Limited Partnership (An Ontario Limited Partnership)

Minimum Subscription:$150,000($50,000 for accredited investors)

416.864.6477 416.864.6485 Fax 1.866.269.7773 Toll Free

26 Wellington Street East, Suite 900 Toronto, ON M5E 1S2

w w w . m g i s e c u r i t i e s . c o m

Joe Sample VP Marketing & Research

416.864.6477 x222 [email protected]

26 Wellington Street East, Suite 900 Toronto, ON M5E 1S2 866.269.7773 Toll Free 416.864.6485 Fax

SECURITIES (USA) INC.

MEMBER OF THE JOVIAN GROUP OF COMPANIES

26 Wellington Street East, Suite 900 Toronto, ON M5E 1S2

Junior Oil & Gas Sector

Brian Kristjansen,Analyst [email protected] 403-705-4969

Jeff Sears,CFA, Associate [email protected]

July 07, 2005

financial


miscellanies

Presentation_PavelPetrycki_v4

Documents

Transcript of Presentation_PavelPetrycki_v4